At Daiichi Sankyo, we believe compassion grows from understanding that no two people suffering from a condition are alike. Each cancer patient has their own set of experiences, challenges and perspect read more

Patient advocacy groups are bringing increased focus to biomarker testing, an underutilized form of testing that is just as important after diagnosis as screening. read more

Gilles Gallant, BPharm, PhD, FOPQ has spent the past three decades pursuing his passion for science and working to unravel the intricacies of cancer. read more

For Daiichi Sankyo, ASCO22 was historic as we demonstrated our bold leadership in oncology with numerous advances across our ADC portfolio. read more